Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fontolizumab in Active Rheumatoid Arthritis
NCT00281294Phase 2Terminated
- Sponsor
- PDL BioPharma
- Start
- Dec 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Fontolizumab with Placebo (2 arms). Primary endpoint: American College of Rheumatology 50% Response at Week 14. Started Dec 2005; status: terminated.
02
Drugs
fontolizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00281294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00281294.